BCT Press Release
Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

Press Release

Terumo BCT Accepting Advancing Apheresis Award 2019 Applications

Annual educational grant of $10,000 for Improved Access and Comfort for Therapeutic Apheresis Patients

​Lakewood, Colo., USA — Applications are now available for the Terumo BCT 2019 Advancing Apheresis award, which this year is open to healthcare providers treating patients with therapeutic apheresis using vein-viewing technology, such as ultrasound or near-infrared devices.

The Advancing Apheresis USD $10,000 grant is open to healthcare providers worldwide. The winner will be chosen by an external committee of key opinion leaders. Considerations include patient care, impact on​ the community and the applicant's history of demonstrating educational leadership. Applications must be received in English by 31 January 2020. Learn more at TERUMOBCT.COM/AdvancingApheresis

Terumo BCT is on a mission to contribute to society through healthcare. This is an opportunity for providers to obtain grant funding aimed at improving the comfort and access to hidden veins for patients who receive therapeutic apheresis. Vein-viewing technology can help improve the comfort of procedures by mapping veins, so they are viewable under the surface of the skin.

-Regis Leonard, Vice President, Therapeutics Systems, Terumo BCT

The grant has a different focus each year. Last year's winner, the University Health Network Apheresis Program in Toronto, Canada is using the educational grant to help fund its Ultrasound-Guided Peripheral Venous Access Training Program with the aim to impact patients and communities managing sickle cell disease.

Now in its sixth year, the Advancing Apheresis grant is part of Terumo BCT's commitment to supporting those who improve patient care using therapeutic apheresis. Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular therapy technologies. The company has customers in about 130 countries.


Therapeutic apheresis involves the separation and removal of blood components. For example, healthcare providers can use Terumo BCT's Spectra Optia® Apheresis System to perform a red blood cell exchange for the management of sickle cell disease. Therapeutic apheresis availability varies by geographic location. It can be used to treat and manage a variety of conditions.​

About Terumo BCT 
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }} {{'SEARCH_MODAL_ENLABEL' | translate }}
{{$index+1}}. {{s.label}}